Background-To evaluate the safety and clinical efficacy of botulinum toxin (BT) in patients with achalasia followed up for six months. Methods-Fifty five symptomatic patients with manometrically proven achalasia were included in a multicentre prospective trial. Before and two weeks and two months after intrasphincteric injection of BT, symptoms of dysphagia, regurgitation, and chest pain were scored on a 0-3 scale, and lower oesophageal sphincter pressure (LOSP) was assessed. The symptom score was determined again at six months, clinical improvement being defined by <3, relapse by >3, and failure as a relapse after two injections or loss to follow up. Results-Except for transient chest or epigastric pain (22%), no side effects were observed. There was a significant decrease in LOSP after treatment. Symptom scores were significantly improved at two weeks (2.0 (SD 1-6)), two months (1.7 (1.8)), and six months (1.9 (2.0)) compared with pretreatment values (5.1 (1.8), p<0001). At six months, 33 patients had clinical improvement (27 after one injection), 17 were considered failures, and five had just relapsed. Although there was a trend for age (older patients being more responsive), age, sex, prior duration of symptoms, initial symptom score, weight loss, LOSP, magnitude of oesophageal contractions, vigorous or non-vigorous achalasia, previous dilatations, and radiological features were not predictive of results. Conclusions-This multicentre series confirms that intrasphincteric injection of BT is a safe procedure, resulting in clinical improvement in 60% of patients with achalasia at six months. The therapeutic role of BT in achalasia needs further evaluation with regard to other alternatives.
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Treatment modalities consist of cardiomyotomy and pneumatic dilatation, both of which are intended to relieve functional obstruction of the distal oesophagus. The symptomatic efficacy of these treatments ranges from 60% to 80%. 27 The risk of perforation after dilatation is estimated to be 1-6%.5 Mortality related to these treatments is about 0 20/. 6 7 Intrasphincteric injection of botulinum toxin (BT) has been recently proposed as an alternative to pneumatic dilatation or surgery in the treatment of achalasia.8-'0 BT has been shown to inhibit acetylcholine release from nerve endings, thereby inducing muscular paresis. "-'3 The effect of BT is reversible due to the sprouting of terminal axons that form new synaptic contacts on adjacent muscle fibres.'4 BT has been used therapeutically in diseases producing hypertonia of skeletal muscles," 13 "5 but its use in smooth muscle is very recent. In vitro studies have shown that BT is also able to inhibit electrically stimulated smooth muscle contraction by blocking the presynaptic release of acetylcholine, without affecting the non-adrenergic non-cholinergic response.'6 17 Pasricha et al showed that injection of BT into the LOS of piglets strongly decreased resting LOS tone.'8 In a single centre trial, this same group recently reported that BT can be used for the treatment of achalasia. Their initial experience showed a 64% improvement rate (20/31 patients) at six months.8-'0 However, it has not yet been clearly established whether these results can be reproduced in less specialised centres and in conditions of routine practice.
In this context, we conducted a prospective multicentre study of BT in achalasia in order to assess the feasibility of treatment as well as to provide additional data on its efficacy and safety.
Patients and methods

PATIENTS
The diagnosis of achalasia was manometrically determined on the basis of complete aperistalsis, together with either hypertonia of the LOS or incomplete relaxations of the LOS.'
Symptomatic patients with achalasia (as defined above) were included. Patients under 18 years of age or over 80, pregnant or breastfeeding women, patients with previous oesophageal myotomy or those with secondary achalasia, and patients in whom BT was contraindicated (those using antibiotics, myorelaxants, or curare, or those with muscular upper gastrointestinal endoscopy was performed. BT was injected through a sclerotherapy needle (TW IV 6 c, length 6 mm, diameter 0 7 mm, ABS, St Die, France) into the four quadrants of the LOS (20 U/ml saline, total dose 80 U). To rinse the residual volume from the needle (0 5 ml), an additional injection of 1 ml of saline was performed after each BT injection. The patient was allowed to eat on the following day.
FOLLOW UP VISITS Visits were systematically scheduled at two weeks and two and six months after BT injection ( fig 1) . In patients who showed no (or insufficient) improvement two weeks after the first injection, as well as in those whose symptoms recurred during the six month follow up, a second injection was proposed (using the same procedure). If symptoms recurred after the second injection, patients were withdrawn and considered to be failures.
CLINICAL ASSESSMENT
Symptomatic response was evaluated using a modified score according to Eckardt et al,3 which was the sum of the individual scores for dysphagia, regurgitation, and chest pain (table 1 ). An adjectival scale of therapeutic efficacy was also proposed to patients who chose between "excellent", "good", "tolerable", and "bad", according to their own perceptions. In addition to undergoing immediate follow up after injections, patients were questioned about the occurrence of potential side effects from the injections, especially fever, symptoms of gastro-oesophageal reflux, and chest pain.
ADDITIONAL PROCEDURES
Two weeks and two months following injection, LOS pressure was manometrically measured, and 24 hour pH monitoring was performed. In addition, in two centres, the isotopic oesophageal emptying fraction was determined for solids and liquids ( fig 1) .
Oesophageal pH monitoring
Twenty four hour pH monitoring was conducted according to the usual procedures of each centre. After nasal introduction, the electrode was placed 5 cm above the LOS, which had been previously located by manometry. Oesophageal acid exposure was expressed as the percentage of total time below pH 4, with a cut-off value 4-2% above pH 4 as the upper limit of normality. 27 26 37
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At week 2, 41 patients showed clinical improvement (74 5%). Among the 14 patients with failure, three were excluded from the trial and 11 received a second injection before month 2. Two of these 11 patients showed clinical improvement at month 6. At month 2, 38 patients showed clinical improvement (69%), nine had relapse (16%), and eight had failure (15%). Among the 41 patients showing clinical improvement at week 2, seven received a second injection between months 2 and 6; four of these seven patients showed clinical improvement at month 6. At month 6, 33 patients (27 with one injection) showed clinical improvement (60%), five had a relapse (9%), and 17 had failure (31%) (four were lost to follow up). The probability of clinical improvement at six months after one BT injection was 52% (fig 2) . Overall, scores at month 6 were <2 in 31 patients, <1 in 22 patients, and null in eight patients.
Six of the 18 patients (33%) who received a second injection achieved sustained clinical improvement at month 6.
There were no significant differences between the seven centres which had five or more patients. The clinical improvement rate at month 6 ranged from 50% to 80%.
CHANGES IN OESOPHAGEAL FUNCTION (table 4)
In all patients but one, manometry showed the persistence of complete oesophageal aperistalsis (fig 3 shows changes in LOS pressure).
Among the 29 patients who had pH monitoring at two months, abnormal oesophageal acid exposure was recorded in only one (percentage of time less than pH 4: 0% at inclusion, 6 4% at two weeks, and 8 4 % at two months), and there were no symptoms of gastro-oesophageal reflux disease.
There was a statistically significant improvement in scintigraphic parameters (fig 4) . OUTCOME PREDICTORS Therapeutic response was not significantly affected by age, sex (p=0.51), previous pneumatic dilatation (p=0.48), prior duration of symptoms, initial weight loss, initial score, initial LOS pressure, diameter of oesophagus, or amplitude of oesophageal contractions (table 5) . These findings remained valid even when the five patients who had just relapsed at six months were considered as responders, in which case the trend towards an age difference between responders (56-0 (14-7) years, n=38) and non-responders (47-6 (13-7) years, n=17, p=0 053) was strengthened. Clinical improvement at six months was more frequently observed in patients with vigorous achalasia (15/22; 68-2%) than in those with classic achalasia (18/33; 54-5%), but the difference was not statistically significant (table 5) . Only Spearman correlation coefficients for scintigraphy of liquids at one minute (p=0-369, n=49) and for symptom score (p=-0-565, n=5 1) were not significantly different (p>005, absolute value). The other coefficients were significantly different, indicating that the time course between symptom score and the studied parameter was different.
Discussion
The results of the present study show that intrasphincteric injection of BT is a safe procedure, resulting in clinical improvement in 60% of patients with achalasia at six months. These results clearly confirm and extend those of Pasricha et al. 8 9 Moreover, the lack of significantly different results between centres suggests that this therapeutic procedure is highly feasible for use in non-specialised centres.
The multicentre design of our study allowed us to enrol 55 consecutive patients within a relatively short period. With regard to age and disease characteristics, our study population was quite representative of achalasia and very similar to populations reported in other studies.3 '4 21-23 Interestingly, the marked weight loss noticed in two thirds of our patients 
